| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $269.8M | +16.0% |
| SG&A Expense | $63.6M | +46.9% |
| Operating Income | -$333.4M | -20.8% |
| Income Tax | $0 | — |
| Net Income | -$328.9M | -28.6% |
| EPS (Basic) | -$2.16 | -11.3% |
| EPS (Diluted) | -$2.16 | -11.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $312.0M | +217.8% |
| Current Assets | $910.4M | +207.1% |
| Total Assets | $937.6M | +185.9% |
| Current Liabilities | $64.0M | +14.8% |
| Long-term Debt | $222.9M | — |
| Total Liabilities | $301.2M | +320.7% |
| Stockholders' Equity | $636.4M | +148.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$264.4M | -27.3% |
| Capital Expenditures | $1.6M | +171.2% |
| Investing Cash Flow | -$399.5M | -1143.8% |
| Financing Cash Flow | $878.2M | +309.5% |
| Free Cash Flow | -$266.0M | -27.7% |